According to Renfu Pharmaceutical's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., recently received a “Notice of Acceptance” for drug registration and marketing license for pregabalin extended-release tablets approved by the State Drug Administration. The drug is a chemical drug, which is mainly used clinically to treat neuropathic pain related to diabetic peripheral neuropathy and post-herpes zoster neuralgia. Up to now, Yichang Renfu has invested about 62 million yuan in R&D on this project. The acceptance of this application marks that the registration of this domestically produced drug has entered the review stage. If successfully approved, it will enrich the company's product line.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.